BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 12226744)

  • 1. A key role of the hSNF5/INI1 tumour suppressor in the control of the G1-S transition of the cell cycle.
    Versteege I; Medjkane S; Rouillard D; Delattre O
    Oncogene; 2002 Sep; 21(42):6403-12. PubMed ID: 12226744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Re-expression of hSNF5/INI1/BAF47 in pediatric tumor cells leads to G1 arrest associated with induction of p16ink4a and activation of RB.
    Betz BL; Strobeck MW; Reisman DN; Knudsen ES; Weissman BE
    Oncogene; 2002 Aug; 21(34):5193-203. PubMed ID: 12149641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P16INK4a is required for hSNF5 chromatin remodeler-induced cellular senescence in malignant rhabdoid tumor cells.
    Oruetxebarria I; Venturini F; Kekarainen T; Houweling A; Zuijderduijn LM; Mohd-Sarip A; Vries RG; Hoeben RC; Verrijzer CP
    J Biol Chem; 2004 Jan; 279(5):3807-16. PubMed ID: 14604992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell cycle arrest and repression of cyclin D1 transcription by INI1/hSNF5.
    Zhang ZK; Davies KP; Allen J; Zhu L; Pestell RG; Zagzag D; Kalpana GV
    Mol Cell Biol; 2002 Aug; 22(16):5975-88. PubMed ID: 12138206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Knock down of hSNF5/Ini1 causes cell cycle arrest and apoptosis in a p53-dependent manner.
    Kato H; Honma R; Sanda T; Fujiwara T; Ito E; Yanagisawa Y; Imai J; Okamoto T; Watanabe S
    Biochem Biophys Res Commun; 2007 Sep; 361(3):580-5. PubMed ID: 17669367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The tumor suppressor hSNF5/INI1 modulates cell growth and actin cytoskeleton organization.
    Medjkane S; Novikov E; Versteege I; Delattre O
    Cancer Res; 2004 May; 64(10):3406-13. PubMed ID: 15150092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RhoA-dependent regulation of cell migration by the tumor suppressor hSNF5/INI1.
    Caramel J; Quignon F; Delattre O
    Cancer Res; 2008 Aug; 68(15):6154-61. PubMed ID: 18676838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reexpression of hSNF5 in malignant rhabdoid tumor cell lines causes cell cycle arrest through a p21(CIP1/WAF1)-dependent mechanism.
    Kuwahara Y; Charboneau A; Knudsen ES; Weissman BE
    Cancer Res; 2010 Mar; 70(5):1854-65. PubMed ID: 20179200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The tumour suppressor hSNF5/INI1 controls the differentiation potential of malignant rhabdoid cells.
    Albanese P; Belin MF; Delattre O
    Eur J Cancer; 2006 Sep; 42(14):2326-34. PubMed ID: 16908131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chromatin remodeling factor encoded by ini1 induces G1 arrest and apoptosis in ini1-deficient cells.
    Ae K; Kobayashi N; Sakuma R; Ogata T; Kuroda H; Kawaguchi N; Shinomiya K; Kitamura Y
    Oncogene; 2002 May; 21(20):3112-20. PubMed ID: 12082626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aurora A is a repressed effector target of the chromatin remodeling protein INI1/hSNF5 required for rhabdoid tumor cell survival.
    Lee S; Cimica V; Ramachandra N; Zagzag D; Kalpana GV
    Cancer Res; 2011 May; 71(9):3225-35. PubMed ID: 21521802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The E2F-family proteins induce distinct cell cycle regulatory factors in p16-arrested, U343 astrocytoma cells.
    Dirks PB; Rutka JT; Hubbard SL; Mondal S; Hamel PA
    Oncogene; 1998 Aug; 17(7):867-76. PubMed ID: 9780003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of the hSNF5 gene concomitantly inactivates p21CIP/WAF1 and p16INK4a activity associated with replicative senescence in A204 rhabdoid tumor cells.
    Chai J; Charboneau AL; Betz BL; Weissman BE
    Cancer Res; 2005 Nov; 65(22):10192-8. PubMed ID: 16288006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclin D1 is overexpressed in atypical teratoid/rhabdoid tumor with hSNF5/INI1 gene inactivation.
    Fujisawa H; Misaki K; Takabatake Y; Hasegawa M; Yamashita J
    J Neurooncol; 2005 Jun; 73(2):117-24. PubMed ID: 15981100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. hSNF5/INI1-deficient tumours and rhabdoid tumours are convergent but not fully overlapping entities.
    Bourdeaut F; Fréneaux P; Thuille B; Lellouch-Tubiana A; Nicolas A; Couturier J; Pierron G; Sainte-Rose C; Bergeron C; Bouvier R; Rialland X; Laurence V; Michon J; Sastre-Garau X; Delattre O
    J Pathol; 2007 Feb; 211(3):323-30. PubMed ID: 17152049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer.
    Versteege I; Sévenet N; Lange J; Rousseau-Merck MF; Ambros P; Handgretinger R; Aurias A; Delattre O
    Nature; 1998 Jul; 394(6689):203-6. PubMed ID: 9671307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SNF5 reexpression in malignant rhabdoid tumors regulates transcription of target genes by recruitment of SWI/SNF complexes and RNAPII to the transcription start site of their promoters.
    Kuwahara Y; Wei D; Durand J; Weissman BE
    Mol Cancer Res; 2013 Mar; 11(3):251-60. PubMed ID: 23364536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retinoblastoma protein in human renal cell carcinoma in relation to alterations in G1/S regulatory proteins.
    Hedberg Y; Ljungberg B; Roos G; Landberg G
    Int J Cancer; 2004 Mar; 109(2):189-93. PubMed ID: 14750168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The requirement for SNF5/INI1 in adipocyte differentiation highlights new features of malignant rhabdoid tumors.
    Caramel J; Medjkane S; Quignon F; Delattre O
    Oncogene; 2008 Mar; 27(14):2035-44. PubMed ID: 17922027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequent deletion of hSNF5/INI1, a component of the SWI/SNF complex, in chronic myeloid leukemia.
    Grand F; Kulkarni S; Chase A; Goldman JM; Gordon M; Cross NC
    Cancer Res; 1999 Aug; 59(16):3870-4. PubMed ID: 10463572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.